Cardiovascular safety of lorcaserin in overweight or obese patients
With the 12 mg dose, 39.4% of participants achieved at least 30% weight loss
Advocacy for Wider Anti-Obesity Drug Coverage Amid Cardiovascular Crisis In a letter addressed to CMS administrator Chiquita Brooks-LaSure, 44 organizations across various disease states commended CMSs decision to cover anti-obesity medications for patients with existing, high-risk cardiovascular disease
Hydration also supports digestion, energy levels and overall medication tolerance
Therefore, in those with slender faces and those concerned with facial aging, understand that despite all the good that medications like Ozempic confer, you may look older as a result
Potential candidates for off-label use: Clinicians may consider GLP-1 therapy for women with PCOS who meet the following criteria: Overweight or obesity (particularly BMI 30 kg/m) with PCOS Insulin resistance or impaired glucose tolerance Inadequate response to lifestyle modification and other treatments No contraindications to GLP-1 therapy Not planning pregnancy in the immediate future Contraindications and precautions: GLP-1 receptor agonists are contraindicated in pregnancy and breastfeeding
